GLP-1 Microdosing in the UK: A Doctor-Led Guide

Could a lower dose of a GLP-1 or related weight-management medicine be appropriate for you?

GLP-1 medicines have transformed medical weight management, but not everyone responds to treatment in exactly the same way. Some patients may experience significant appetite suppression or gastrointestinal side effects at standard doses, while others may be looking for a more gradual, individually tailored approach.

At 121 Clinic, treatment decisions are made on an individual basis by qualified doctors following a medical assessment. Where clinically appropriate, your doctor may discuss dose adjustments or a lower-dose approach as part of personalised treatment.

What is GLP-1 microdosing?

"Microdosing" is a term increasingly used online to describe using a lower dose of a GLP-1 or related weight-management medicine than the dose someone might otherwise take.

It is important to understand that microdosing is not a single standardised medical treatment or universally defined dosing regimen.

Medicines such as semaglutide and tirzepatide have specific licensed dosing schedules and indications. A doctor should therefore determine whether a particular dose is appropriate for an individual patient rather than assuming that a lower dose is automatically safer, better or more effective.

At 121 Clinic, we use the term "microdosing" to describe an individualised approach where a doctor considers whether a lower dose may be clinically appropriate for a particular patient.

Why might someone consider a lower dose?

There are several reasons a doctor may consider adjusting treatment.

These can include:

• sensitivity to medication

• gastrointestinal side effects such as nausea or constipation

• achieving adequate appetite control at a lower dose

• maintaining a satisfactory response without unnecessarily increasing the dose

• individual treatment goals

• previous experience with weight-management medication

• tolerability during dose escalation

The aim is not simply to use the lowest possible dose.

The aim is to find an appropriate and effective dose for the individual patient.

Is a lower dose always better?

No.

A lower dose does not necessarily mean:

• faster weight loss

• fewer side effects

• better long-term results

• greater safety for everyone

• that treatment will work for you

Weight-management medicines require individual assessment and monitoring.

Increasing, reducing or maintaining a dose should be based on factors such as your response, side effects, treatment goals and overall health.

Microdosing and the "lowest effective dose"

At 121 Clinic, we believe medication should be personalised rather than based simply on a target dose.

For some patients, a higher dose may be appropriate.

For others, a lower dose may provide an acceptable balance between benefit and tolerability.

This is why we use the principle of finding an appropriate effective dose, rather than assuming that every patient should progress to the highest available dose.

Your doctor will consider your individual circumstances before recommending a treatment plan.

What medicines can be involved?

Weight-management medicines discussed in relation to "GLP-1 microdosing" may include medicines containing:

• semaglutide, such as Wegovy/Ozempic/Saxenda

• tirzepatide, such as Mounjaro

It is important to distinguish between them.

Semaglutide is a GLP-1 receptor agonist, whereas tirzepatide acts on both the GIP and GLP-1 receptors.

The medicines also have their own licensed indications, dosing schedules, contraindications and prescribing requirements.

Your doctor should determine which medicine, if any, is appropriate for you.

What are the potential advantages of an individualised lower-dose approach?

Where clinically appropriate, a lower-dose approach may help some patients find a balance between treatment benefit and tolerability.

Potential considerations include:

Better tolerability

Some patients experience nausea, vomiting, diarrhoea, constipation, abdominal discomfort or reduced appetite during treatment.

A doctor may consider whether the current dose is appropriate if side effects are problematic.

More gradual treatment

Some patients prefer a more gradual approach to appetite and weight management.

Individual response

People respond differently to weight-management medicines.

One patient's effective dose may not be the same as another patient's.

Long-term treatment planning

Weight management is not simply about reaching a particular number on the scales.

A longer-term plan may include weight loss, maintenance, nutrition, physical activity and medication review.

What are the risks?

Lower-dose treatment is not risk-free.

GLP-1 and related medicines can cause side effects and may not be suitable for everyone.

Depending on the medicine, potential adverse effects can include:

• nausea

• vomiting

• diarrhoea

• constipation

• abdominal discomfort

• reduced appetite

• dehydration

There are also important contraindications, precautions and clinically significant adverse effects that need to be considered before treatment.

This is why we recommend medical assessment rather than purchasing or using medication based solely on advice from social media or online forums.

Does microdosing mean taking tiny amounts of medication?

Not necessarily.

The word "microdosing" is used inconsistently online.

Patients may use it to describe different approaches, including remaining at a lower dose, delaying dose escalation or using a dose below what they expected to require.

There is therefore no single "microdose" that applies to everyone.

Your doctor should determine the appropriate dose and prescribing approach.

Can you stay on a lower dose long term?

This depends on the individual patient, the medicine being prescribed and the clinical response.

If a patient is achieving an appropriate response and tolerating treatment well, the doctor may consider whether further dose escalation is necessary.

Conversely, if weight loss is inadequate or appetite control remains poor, the treatment plan may need to be reviewed.

The decision should be based on clinical assessment rather than a fixed rule.

What happens if you have reached your target weight?

Reaching a target weight does not necessarily mean that treatment should simply stop.

Weight regain can occur after weight loss, particularly if appetite returns and the underlying factors contributing to excess weight have not been addressed.

A maintenance plan may include:

• nutrition

• adequate protein intake

• resistance exercise

• physical activity

• behavioural strategies

• monitoring weight and body composition

• medication review

Your doctor can discuss whether continued treatment, dose adjustment or another approach is appropriate.

Microdosing and nutrition

Medication is only one component of medical weight management.

During weight loss, it is particularly important to maintain adequate nutrition.

We generally encourage patients to focus on:

Protein

Adequate protein can help support muscle preservation during weight loss.

Fibre

Fibre-rich foods can support digestive health and bowel regularity, although individual tolerance is important.

Hydration

Adequate fluid intake is particularly important if appetite and food intake have reduced.

Nutrient-dense foods

Vegetables, fruit, whole grains, pulses, lean protein sources and other nutrient-dense foods can form the basis of a sustainable eating pattern.

Microdosing and muscle preservation

The goal of successful weight management should not simply be a lower number on the scales.

Preserving muscle and maintaining physical function are also important.

Patients using weight-management medication should therefore consider:

• adequate protein

• resistance exercise

• sufficient nutrition

• appropriate rate of weight loss

• regular clinical review

Where available and clinically appropriate, body-composition measurements can provide additional information beyond body weight alone.

Who may benefit from a lower-dose approach?

There is no single patient profile.

A doctor may consider an individualised lower-dose strategy where, for example:

• treatment is effective but side effects become problematic with escalation

• appetite control is satisfactory at a lower dose

• the patient has particular treatment goals

• the balance between benefit and tolerability needs reassessment

However, suitability must be determined individually.

Who should not simply start microdosing themselves?

Patients should not split, dilute, alter or otherwise manipulate medicines unless this is specifically supported by the prescribing instructions and their prescriber.

Nor should patients use a dose obtained from social media, another person's prescription or an unregulated supplier.

Prescription weight-management medicines require appropriate clinical assessment and a legitimate prescribing pathway.

Frequently asked questions

Is GLP-1 microdosing safe?

A lower dose is not automatically safe for everyone. Safety depends on the medicine, the patient's health, other medicines and the clinical circumstances.

Will I lose weight on a lower dose?

Some people may respond to a lower dose, but the response varies considerably. There is no guarantee that a lower dose will produce clinically meaningful weight loss.

Does microdosing cause fewer side effects?

It may improve tolerability for some patients, but lower doses do not eliminate the possibility of side effects.

Can I ask my doctor to keep me on a lower dose?

Yes. This is an appropriate topic to discuss with your prescriber. Your doctor can assess whether maintaining, increasing or reducing the dose is clinically appropriate.

Can I use Mounjaro for microdosing?

Your doctor can discuss your individual response and whether a particular dose is appropriate. Mounjaro contains tirzepatide, which is a GIP and GLP-1 receptor agonist.

Can I use Wegovy for microdosing?

Your doctor can assess whether the prescribed dose and treatment schedule are appropriate for you. Wegovy contains semaglutide, a GLP-1 receptor agonist.

Is microdosing the same as maintenance treatment?

Not necessarily.

A lower dose during active weight loss and a treatment strategy intended to maintain weight after weight loss are different clinical questions.

Why choose 121 Clinic?

121 Clinic provides doctor-led personalised medical weight management.

Our approach combines medical assessment with ongoing consideration of:

• your weight and health history

• current medicines

• treatment goals

• response to treatment

• side effects and tolerability

• nutrition

• physical activity

• longer-term weight maintenance

We do not believe that one dose or one treatment strategy is appropriate for everyone.

Interested in a personalised assessment?

If you are considering GLP-1 treatment or are already taking Mounjaro or Wegovy and would like to discuss whether your current dose is appropriate, a doctor can review your individual circumstances and discuss your options.

Book a consultation with 121 Clinic to discuss personalised medical weight management.